carbamates has been researched along with Atherogenesis in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "EXPANDING OUR KNOWLEDGE: Natural lipocyclocarbamate natural products have provided the inspiration for the first-in-class synthetic phospholipase inhibitor darapladib, currently in phase III clinical trials for the treatment of atherosclerosis." | 3.79 | Nonribosomal assembly of natural lipocyclocarbamate lipoprotein-associated phospholipase inhibitors. ( Johnston, CW; Khyzha, N; Magarvey, NA; Zvanych, R, 2013) |
| "Experimental diabetes mellitus was produced by a single intraperitoneal injection of STZ (55mg/kg b." | 1.43 | Antihyperglycemic and antidiabetic effects of Ethyl (S)-2-(1-cyclohexylsulfamide carbamoyloxy) propanoate in streptozotocin-induced diabetic Wistar rats. ( Berredjem, H; Berredjem, M; Bouzerna, N; Cheloufi, H; Réggami, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spinelli, FR | 1 |
| Pecani, A | 1 |
| Ciciarello, F | 1 |
| Colasanti, T | 1 |
| Di Franco, M | 1 |
| Miranda, F | 1 |
| Conti, F | 1 |
| Valesini, G | 1 |
| Alessandri, C | 1 |
| Apostolov, EO | 1 |
| Ok, E | 1 |
| Burns, S | 1 |
| Nawaz, S | 1 |
| Savenka, A | 1 |
| Shah, S | 1 |
| Basnakian, AG | 1 |
| Ketelhuth, DF | 1 |
| Hermansson, A | 1 |
| Hlawaty, H | 1 |
| Letourneur, D | 1 |
| Yan, ZQ | 2 |
| Bäck, M | 2 |
| Réggami, Y | 1 |
| Berredjem, H | 1 |
| Cheloufi, H | 1 |
| Berredjem, M | 1 |
| Bouzerna, N | 1 |
| Lenglet, S | 1 |
| Thomas, A | 1 |
| Soehnlein, O | 1 |
| Montecucco, F | 1 |
| Burger, F | 1 |
| Pelli, G | 1 |
| Galan, K | 1 |
| Cravatt, B | 1 |
| Staub, C | 1 |
| Steffens, S | 1 |
| Johnston, CW | 1 |
| Zvanych, R | 1 |
| Khyzha, N | 1 |
| Magarvey, NA | 1 |
| Kodvawala, A | 1 |
| Ghering, AB | 1 |
| Davidson, WS | 1 |
| Hui, DY | 1 |
| Bu, DX | 1 |
| Bränström, R | 1 |
| Sheikine, Y | 1 |
| Hansson, GK | 1 |
| Allred, KF | 1 |
| Smart, EJ | 1 |
| Wilson, ME | 1 |
| Wang, Z | 1 |
| Nicholls, SJ | 1 |
| Rodriguez, ER | 1 |
| Kummu, O | 1 |
| Hörkkö, S | 1 |
| Barnard, J | 1 |
| Reynolds, WF | 1 |
| Topol, EJ | 1 |
| DiDonato, JA | 1 |
| Hazen, SL | 1 |
| Rader, DJ | 1 |
| Ischiropoulos, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Follow-up of Anti-Carbamylated Antibody Status in Rheumatoid Arthritis Patients at 6, 12 and 18 Months[NCT02958319] | 278 participants (Actual) | Observational | 2016-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To explore the clinical differences in activity indexes (DAS28-ESR) at 6, 12 and 18 months of follow-up according the anti-CarP status.~The DAS28 is a composite score derived from 4 measures, one of them can be the erythrocyte sedimentation rate (ESR). We will be using the DAS28-ESR version. To calculate the DAS28-ESR the rheumatologist or specialist nurse will:- count the number of swollen joints (out of the 28), count the number of tender joints (out of the 28), take blood to measure ESR, ask participants to make a 'global assessment of health' (indicated by marking a 10 cm line between very good and very bad).~DAS28-ESR is calculated with classic calculators and resulting values are interpreted as follows:~<2.6: disease remission 2.6 - 3.2: low disease activity 3.2 - 5.1: moderate disease activity >5.1: high disease activity" (NCT02958319)
Timeframe: 6, 12 and 18 Months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 6 MONTHS | 12 MONTHS | 18 MONTHS | |
| Anti P Carb Negative RA Patients | 3.75 | 3.59 | 3.65 |
| Anti P Carb Positive RA Patients | 3.72 | 3.69 | 3.77 |
11 other studies available for carbamates and Atherogenesis
| Article | Year |
|---|---|
Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients.
Topics: Adult; Aged; Arthritis, Rheumatoid; Atherosclerosis; Autoantibodies; Blood Proteins; Carbamates; Car | 2017 |
Carbamylated-oxidized LDL: proatherosclerotic effects on endothelial cells and macrophages.
Topics: Atherosclerosis; Carbamates; Cell Death; Cells, Cultured; Endothelium, Vascular; Enzyme-Linked Immun | 2013 |
The leukotriene B4 receptor (BLT) antagonist BIIL284 decreases atherosclerosis in ApoE-/- mice.
Topics: Amidines; Animals; Apolipoproteins E; Atherosclerosis; Carbamates; Cytokines; Male; Matrix Metallopr | 2015 |
Antihyperglycemic and antidiabetic effects of Ethyl (S)-2-(1-cyclohexylsulfamide carbamoyloxy) propanoate in streptozotocin-induced diabetic Wistar rats.
Topics: Animals; Atherosclerosis; Bilirubin; Blood Glucose; Body Weight; Carbamates; Creatinine; Diabetes Me | 2016 |
Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice.
Topics: Amides; Amidohydrolases; Animals; Aorta; Aortic Diseases; Apolipoproteins E; Arachidonic Acids; Athe | 2013 |
Nonribosomal assembly of natural lipocyclocarbamate lipoprotein-associated phospholipase inhibitors.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atherosclerosis; Benzaldehydes; Biological Products; | 2013 |
Carboxyl ester lipase expression in macrophages increases cholesteryl ester accumulation and promotes atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Biological Transport; Carbamates; Carboxylesterase; Cer | 2005 |
Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia.
Topics: Amidines; Analysis of Variance; Animals; Atherosclerosis; Blotting, Western; Carbamates; Carotid Art | 2005 |
Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors.
Topics: Animals; Atherosclerosis; Carbamates; Cholesterol; Estrogen Receptor alpha; Female; Furans; HIV Prot | 2006 |
Protein carbamylation links inflammation, smoking, uremia and atherogenesis.
Topics: Animals; Atherosclerosis; Blood Proteins; Carbamates; Cholesterol; Citrulline; Clinical Trials as To | 2007 |
'Multipurpose oxidase' in atherogenesis.
Topics: Animals; Apoptosis; Atherosclerosis; Carbamates; Cardiovascular Diseases; Cell Proliferation; Citrul | 2007 |